Michael T. Watkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael T. Watkins has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Brian Furner
Department of Pediatrics, University of Chicago, Chicago, IL
2 shared publications Harry M. Salinas
Division of Plastic and Reconstructive Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA
2 shared publicationsMichael C. McCormack
Division of Plastic and Reconstructive Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA
2 shared publications- Robert W. Redmond
Wellman Center for Photomedicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
2 shared publications - Saiqa I. Khan
Division of Plastic and Reconstructive Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA
2 shared publications - Samuel Louis Volchenboum
Department of Pediatrics, University of Chicago, Chicago, IL
2 shared publications
Latest Publications
- Open Access
- 25 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 579-588
International neuroblastoma risk group consortium: a model of networking for rare cancers
It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve this goal. Strategies developed for neuroblastoma are an exemplar for other rare malignancies. Data from an initial cohort of 8800 patients were transferred to the INRG Data Commons, and a data-sharing model was developed. Currently, information on more than 25 000 patients is available to the research community. The INRG staging and risk classification systems have led to harmonized approaches for therapeutic groupings. INRG consensus manuscripts have led to uniform criteria for classifying biological data, evaluating the extent of disease, and defining treatment response. More than 40 INRG research studies have been performed by investigators from around the world, including analyses of rare patients, which would not otherwise be possible. The success of this approach for neuroblastoma has been leveraged to create the Pediatric Cancer Data Commons and the Data for the Common Good. Efforts to enrich the INRG Commons with additional genomic and biomarker data, extracted electronic health records, and digital medical images are ongoing. The international networking model developed by the INRG Task Force has led to new research discoveries and progress in neuroblastoma. The approach has now been applied to 16 other cancers and conditions, including rhabdomyosarcoma, germ cell tumor, Lynch syndrome, and cancer predisposition. This framework of international collaboration and data sharing serves as a model for advancing rare adult malignancies.
- 25 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 579-588
Open AccessInternational neuroblastoma risk group consortium: a model of networking for rare cancers
It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve this goal. Strategies developed for neuroblastoma are an exemplar for other rare malignancies. Data from an initial cohort of 8800 patients were transferred to the INRG Data Commons, and a data-sharing model was developed. Currently, information on more than 25 000 patients is available to the research community. The INRG staging and risk classification systems have led to harmonized approaches for therapeutic groupings. INRG consensus manuscripts have led to uniform criteria for classifying biological data, evaluating the extent of disease, and defining treatment response. More than 40 INRG research studies have been performed by investigators from around the world, including analyses of rare patients, which would not otherwise be possible. The success of this approach for neuroblastoma has been leveraged to create the Pediatric Cancer Data Commons and the Data for the Common Good. Efforts to enrich the INRG Commons with additional genomic and biomarker data, extracted electronic health records, and digital medical images are ongoing. The international networking model developed by the INRG Task Force has led to new research discoveries and progress in neuroblastoma. The approach has now been applied to 16 other cancers and conditions, including rhabdomyosarcoma, germ cell tumor, Lynch syndrome, and cancer predisposition. This framework of international collaboration and data sharing serves as a model for advancing rare adult malignancies.
- Open Access
- 1 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400009
Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module
PURPOSE: Although the International Neuroblastoma Risk Group Data Commons (INRGdc) has enabled seminal large cohort studies, the research is limited by the lack of real-world, electronic health record (EHR) treatment data. To address this limitation, we evaluated the feasibility of extracting treatment data directly from EHRs using the REDCap Clinical Data Interoperability Services (CDIS) module for future submission to the INRGdc. METHODS: Patients enrolled on the Children's Oncology Group neuroblastoma biology study ANBL00B1 (ClinicalTrials.gov identifier: NCT00904241 ) who received care at the University of Chicago (UChicago) or the Vanderbilt University Medical Center (VUMC) after the go-live dates for the Fast Healthcare Interoperability Resources (FHIR)–compliant EHRs were identified. Antineoplastic drug orders were extracted using the CDIS module. To validate the CDIS output, antineoplastic agents extracted through FHIR were compared with those queried through EHR relational databases (UChicago's Clinical Research Data Warehouse and VUMC's Epic Clarity database) and manual chart review. RESULTS: The analytic cohort consisted of 41 patients at UChicago and 32 VUMC patients. Antineoplastic drug orders were identified in the extracted EHR records of 39 (95.1%) UChicago patients and 26 (81.3%) VUMC patients. Manual chart review confirmed that patients with missing (n = 8) or discontinued (n = 1) orders in the CDIS output did not receive antineoplastic agents during the timeframe of the study. More than 99% of the antineoplastic drug orders in the EHR relational databases were identified in the corresponding CDIS output. CONCLUSION: Our results demonstrate the feasibility of extracting EHR treatment data with high fidelity using HL7-FHIR via REDCap CDIS for future submission to the INRGdc.
- 1 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400009
Open AccessExtracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module
PURPOSE: Although the International Neuroblastoma Risk Group Data Commons (INRGdc) has enabled seminal large cohort studies, the research is limited by the lack of real-world, electronic health record (EHR) treatment data. To address this limitation, we evaluated the feasibility of extracting treatment data directly from EHRs using the REDCap Clinical Data Interoperability Services (CDIS) module for future submission to the INRGdc. METHODS: Patients enrolled on the Children's Oncology Group neuroblastoma biology study ANBL00B1 (ClinicalTrials.gov identifier: NCT00904241 ) who received care at the University of Chicago (UChicago) or the Vanderbilt University Medical Center (VUMC) after the go-live dates for the Fast Healthcare Interoperability Resources (FHIR)–compliant EHRs were identified. Antineoplastic drug orders were extracted using the CDIS module. To validate the CDIS output, antineoplastic agents extracted through FHIR were compared with those queried through EHR relational databases (UChicago's Clinical Research Data Warehouse and VUMC's Epic Clarity database) and manual chart review. RESULTS: The analytic cohort consisted of 41 patients at UChicago and 32 VUMC patients. Antineoplastic drug orders were identified in the extracted EHR records of 39 (95.1%) UChicago patients and 26 (81.3%) VUMC patients. Manual chart review confirmed that patients with missing (n = 8) or discontinued (n = 1) orders in the CDIS output did not receive antineoplastic agents during the timeframe of the study. More than 99% of the antineoplastic drug orders in the EHR relational databases were identified in the corresponding CDIS output. CONCLUSION: Our results demonstrate the feasibility of extracting EHR treatment data with high fidelity using HL7-FHIR via REDCap CDIS for future submission to the INRGdc.
- Open Access
- 2 June 2021
- Published by Wiley
- Vol. 2022, 1145-1152
LocalVar: a local variant collection manager to asynchronously detect synonyms, HGVS expression changes, and variant interpretation changes from ClinVar
While there are several public repositories of biological sequence variation data and associated annotations, there is little open-source tooling designed specifically for the upkeep of local collections of variant data. Many clinics curate and maintain such local collections and are burdened by frequent changes in the representation of those variants and evolving interpretations of clinical significance. A dictionary of genetic variants from the Huntsman Cancer Institute was analyzed over a period of two years and used to inform the development of LocalVar. This tool is institution-agnostic and uses publicly available ClinVar files to provide the following functionality: auto-complete search bar to pre-empt duplicate entries; single or bulk new variant record entry; auto-detection and merge suggestions for duplicate variant records; auto-detection and merge suggestions for variant records with HGVS expressions that are marked as synonyms in ClinVar; asynchronous suggestion of HGVS expression or variant interpretation updates; history tracking of additions, merges, updates, or other manual edits made to variant records; and the easy export of the collection (.csv), edit history (.json), or HGVS synonym bins (.json).
- 2 June 2021
- Published by Wiley
- Vol. 2022, 1145-1152
Open AccessLocalVar: a local variant collection manager to asynchronously detect synonyms, HGVS expression changes, and variant interpretation changes from ClinVar
While there are several public repositories of biological sequence variation data and associated annotations, there is little open-source tooling designed specifically for the upkeep of local collections of variant data. Many clinics curate and maintain such local collections and are burdened by frequent changes in the representation of those variants and evolving interpretations of clinical significance. A dictionary of genetic variants from the Huntsman Cancer Institute was analyzed over a period of two years and used to inform the development of LocalVar. This tool is institution-agnostic and uses publicly available ClinVar files to provide the following functionality: auto-complete search bar to pre-empt duplicate entries; single or bulk new variant record entry; auto-detection and merge suggestions for duplicate variant records; auto-detection and merge suggestions for variant records with HGVS expressions that are marked as synonyms in ClinVar; asynchronous suggestion of HGVS expression or variant interpretation updates; history tracking of additions, merges, updates, or other manual edits made to variant records; and the easy export of the collection (.csv), edit history (.json), or HGVS synonym bins (.json).
- 1 April 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 219 (4) , 557-562
The impact of race on choice of location for elective surgical care in New York city
- 1 April 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 219 (4) , 557-562
The impact of race on choice of location for elective surgical care in New York city
- Open Access
- 8 August 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (8)
Photochemical Tissue Passivation Reduces Vein Graft Intimal Hyperplasia in a Swine Model of Arteriovenous Bypass Grafting
Background: Bypass grafting remains the standard of care for coronary artery disease and severe lower extremity ischemia. Efficacy is limited by poor long‐term venous graft patency secondary to intimal hyperplasia ( IH ) caused by venous injury upon exposure to arterial pressure. We investigate whether photochemical tissue passivation ( PTP ) treatment of vein grafts modulates smooth muscle cell ( SMC ) proliferation and migration, and inhibits development of IH . Methods and Results: PTP was performed at increasing fluences up to 120 J/cm 2 on porcine veins. Tensiometry performed to assess vessel elasticity/stiffness showed increased stiffness with increasing fluence until plateauing at 90 J/cm 2 (median, interquartile range [ IQR ]). At 90 J/cm 2 , PTP ‐treated vessels had a 10‐fold greater Young's modulus than untreated controls (954 [ IQR , 2217] vs 99 kPa [ IQR , 63]; P =0.03). Each pig received a PTP ‐treated and untreated carotid artery venous interposition graft. At 4‐weeks, intimal/medial areas were assessed. PTP reduced the degree of IH by 66% and medial hypertrophy by 49%. Intimal area was 3.91 ( IQR , 1.2) and 1.3 mm 2 ( IQR , 0.97; P ≤0.001) in untreated and PTP ‐treated grafts, respectively. Medial area was 9.2 ( IQR , 3.2) and 4.7 mm 2 ( IQR , 2.0; P ≤0.001) in untreated and PTP ‐treated grafts, respectively. Immunohistochemistry was performed to assess alpha‐smooth muscle actin ( SMA ) and proliferating cell nuclear antigen ( PCNA ). Objectively, there were less SMA ‐positive cells within the intima/media of PTP ‐treated vessels than controls. There was an increase in PCNA ‐positive cells within control vein grafts (18% [ IQR , 5.3]) versus PTP ‐treated vein grafts (5% [ IQR , 0.9]; P =0.02). Conclusions: By strengthening vein grafts, PTP decreases SMC proliferation and migration, thereby reducing IH .
- 8 August 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (8)
Open AccessPhotochemical Tissue Passivation Reduces Vein Graft Intimal Hyperplasia in a Swine Model of Arteriovenous Bypass Grafting
Background: Bypass grafting remains the standard of care for coronary artery disease and severe lower extremity ischemia. Efficacy is limited by poor long‐term venous graft patency secondary to intimal hyperplasia ( IH ) caused by venous injury upon exposure to arterial pressure. We investigate whether photochemical tissue passivation ( PTP ) treatment of vein grafts modulates smooth muscle cell ( SMC ) proliferation and migration, and inhibits development of IH . Methods and Results: PTP was performed at increasing fluences up to 120 J/cm 2 on porcine veins. Tensiometry performed to assess vessel elasticity/stiffness showed increased stiffness with increasing fluence until plateauing at 90 J/cm 2 (median, interquartile range [ IQR ]). At 90 J/cm 2 , PTP ‐treated vessels had a 10‐fold greater Young's modulus than untreated controls (954 [ IQR , 2217] vs 99 kPa [ IQR , 63]; P =0.03). Each pig received a PTP ‐treated and untreated carotid artery venous interposition graft. At 4‐weeks, intimal/medial areas were assessed. PTP reduced the degree of IH by 66% and medial hypertrophy by 49%. Intimal area was 3.91 ( IQR , 1.2) and 1.3 mm 2 ( IQR , 0.97; P ≤0.001) in untreated and PTP ‐treated grafts, respectively. Medial area was 9.2 ( IQR , 3.2) and 4.7 mm 2 ( IQR , 2.0; P ≤0.001) in untreated and PTP ‐treated grafts, respectively. Immunohistochemistry was performed to assess alpha‐smooth muscle actin ( SMA ) and proliferating cell nuclear antigen ( PCNA ). Objectively, there were less SMA ‐positive cells within the intima/media of PTP ‐treated vessels than controls. There was an increase in PCNA ‐positive cells within control vein grafts (18% [ IQR , 5.3]) versus PTP ‐treated vein grafts (5% [ IQR , 0.9]; P =0.02). Conclusions: By strengthening vein grafts, PTP decreases SMC proliferation and migration, thereby reducing IH .
- Open Access
- 8 June 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 205 (1) , 49-58
Revascularization and muscle adaptation to limb demand ischemia in diet-induced obese mice
- 8 June 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 205 (1) , 49-58
Open AccessRevascularization and muscle adaptation to limb demand ischemia in diet-induced obese mice
- Open Access
- 8 April 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 65 (1) , 190-196
Prevention of vein graft intimal hyperplasia with photochemical tissue passivation
- 8 April 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 65 (1) , 190-196
Open AccessPrevention of vein graft intimal hyperplasia with photochemical tissue passivation